Refine by
Brain Tumor Articles & Analysis
79 news found
Ilkka Haapala’s PhD dissertation explored the possibility of differentiating tumour types and specific mutations based on DMS. We want to congratulate Ilkka on his successful defense of the dissertation at Tampere University on 11.10.2024! IonVision was used as the DMS in several of the studies. The dissertation found that DMS can be used to identify the most common brain tumour ...
(“Anuncia” or the “Company”), a Company specializing in advancing innovations for implantable and external cerebrospinal fluid (CSF) management systems, is pleased to announce the successful first implant of the Company’s FDA-cleared ReFlow™ Mini Flusher device in tandem with a “sonolucent” cranial plate (Clearfit® Cover, Longeviti, Baltimore ...
Through our neoantigen research service, Alfa Cytology identifies unique cancer-carrying genes by sequencing tumor cell genes to predict immune presentation affinity. Then we screen out characteristic neoantigens encoded, hoping to make a huge contribution to tumor ...
CD BioSciences now offers a comprehensive portfolio of Nervous System Tissue Microarrays, including Brain Tissue Microarrays and Head & Neck Tissue Microarrays. This comprehensive offering provides researchers with a powerful tool for studying various neurological disorders, including brain tumors, head and neck cancers, and neurodegenerative ...
Bioprinted heart, liver, nerve, spinal cord, and brain tumor tissues have been successfully developed by the Chen group. ...
ByCELLINK
Synaptive Medical has received $900,000 in support from the Ontario government through the Ontario Together Fund. This funding will support Synaptive Medical’s $2.8 million project to expand manufacturing and research and development activities related to the company’s head-only Magnetic Resonance Imaging (MRI) system. The Synaptive MRI is a 0.5T system that was designed to overcome ...
Roswell Biotechnologies, Inc., the molecular electronics company, announced today the formation of its Scientific Advisory Board (SAB). Comprised of industry and academic leaders in science and technology, the new SAB will be instrumental in the final stages of development and commercialization of the company's molecular electronics chip, a fully scalable universal biosensor capable of seeing ...
” “We are excited to work with Nautilus in being able to characterize the proteome in DIPG to further our understanding of this aggressive brain cancer,” said Dr. Stephanie Pond, Vice President of Emerging Opportunities at TGen. DIPG is a brain tumor that occurs in an area of the brainstem (the pons) which controls many of the ...
Reglagene's CEO Richard Austin presented at JPM #BiotechShowcase this afternoon. This was a very exciting presentation as Richard announced the selection of Reglagene's Clinical Candidate for brain ...
Their annual meeting features research and educational sessions on brain tumors, including the latest on diagnosis and treatments. The two xCures posters will be presented at the Poster Session on Friday, November 18, 2022, from 7:30 pm-9:30 pm EST, and are entitled: EPCO-10: Systems biology-based therapeutic predictions with gbmSYGNAL and clinical correlates ...
ByxCures
The study published as part of the special issue of Cancers “Novel Techniques and Technology for Treatment of Brain Tumors”, reports that Spermidine/spermine N1-acetyltransferase 1 (SAT1) inhibition using an ionizable lipid nanoparticle-based siRNA delivery system appears to provide a safe and effective method to sensitizing GB cells to radiation and ...
“Glioblastoma remains one of the most aggressive and difficult to treat cancers globally and we believe that targeted radiotherapy and particularly ITM-31 can make a significant impact for patients by selectively eliminating tumor remnants post-surgery,” said Steffen Schuster, CEO of ITM. ...
Flowonix Medical Inc. of New Jersey, and Colorado-based Cerebral Therapeutics, announced today the first patients implanted with the Prometra II Programmable Infusion System in the Australian Direct Drug Administration for Refractory Epilepsy (ADDRESS) clinical trial at St. Vincent's Hospital, Melbourne, Australia. The jointly developed therapy features a micro-infusion device that tightly ...
Upon closing of their proposed Business Combination, Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., and is expected to be listed on NASDAQ under the symbol, “OCEA”. Providence, RI and New York, NY, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare Acquisition Corp. ...
New York, NY and Providence, RI, Sept. 19, 2022 (GLOBE NEWSWIRE) -- As previously announced, on August 31, 2022, Aesther Healthcare Acquisition Corp. (“Aesther”) (NASDAQ: AEHA) entered into definitive merger agreement with Ocean Biomedical, Inc. Aesther announced today that it has paid, and that Continental Stock Transfer & Trust Company has received, $1,050,000 from Aesther ...
In turn, interventions based on this master pathway control the ability of tumor cells to develop, spread to the lung, and grow once they’re in the ...
“Glioblastoma Multiforme is the deadliest form of Brain Cancer, yet the standard of care has not changed for newly diagnosed GBM since 2005. ...
Aesther Healthcare (NASDAQ:AEHA) announced this morning that it has inked a common stock purchase agreement with White Lion Capital that will provide up to $75 million to its combination target Ocean Biomedical. Following close, Ocean may direct White Lion to purchase shares in the company worth up to $2 million or 67% of the five-day average daily trading volume. White Lion previously signed an ...
Structurally, PDC mainly contains three elements—cytotoxin, linker, and targeted peptide, in which a specific peptide sequence covalently connects with the cytotoxin through a decomposable linker. PDCs can be used as tumor-targeting vectors, imaging agents, and diagnostic tools. They have a wide range of indications, involving brain tumor, ...
CHI3L1 is also an excellent biomarker: with serum and tissue levels which predict severity and prognosis in multiple tumor types. Ocean Biomedical seeks to address major unmet needs in its initial indications with the mAb for lung cancer and the bispecific antibody for brain cancer. ...